Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | F2R | P25116 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30919787 | 0.93 | MEN1 (0.55) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL12818553 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL12966315 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL12818111 | 0.90 | ALDH1A1 (0.57) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL22412622 | 0.90 | ALDH1A1 (0.60) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL18768309 | 0.90 | ALDH1A1 (0.60) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL30229920 | 0.88 | MAPT (0.55) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL8235662 | 0.88 | KMT2A (0.55) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL7290589 | 0.86 | CHRM1 (0.51) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL23261166 | 0.85 | MEN1 (0.60) | ALDH1A1MEN1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116895-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3937934-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113924094-A | Ester-substituted ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185915-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2017066705-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE AGAINST STRESS GRANULES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116895-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885MEN1 3533/4885MAPT 2258/4885 |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885MEN1 3533/4885MAPT 2258/4885 |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885MEN1 3533/4885MAPT 2258/4885 |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885MEN1 3533/4885MAPT 2258/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885MEN1 3533/4885MAPT 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.